{"id":"glsi-100","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Flu-like symptoms"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL3663407","moleculeType":"Small molecule","molecularWeight":"409.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug is manufactured by isolating a patient's dendritic cells, loading them with tumor-associated peptide antigens (particularly HER2), and reinfusing them to prime T-cell responses against cancer. This personalized immunotherapy approach aims to generate durable anti-tumor immunity by activating both CD4+ and CD8+ T cells against the patient's own malignant cells.","oneSentence":"GLSI-100 is an autologous dendritic cell vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:26.719Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive breast cancer (adjuvant setting)"}]},"trialDetails":[{"nctId":"NCT05232916","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects","status":"RECRUITING","sponsor":"Greenwich LifeSciences, Inc.","startDate":"2022-08-11","conditions":"Breast Cancer","enrollment":750}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GLSI-100","genericName":"GLSI-100","companyName":"Greenwich LifeSciences, Inc.","companyId":"greenwich-lifesciences-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"GLSI-100 is an autologous dendritic cell vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. Used for HER2-positive breast cancer (adjuvant setting).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}